F Wolfe

Summary

Affiliation: National Data Bank for Rheumatic Diseases
Country: USA

Publications

  1. Wolfe F, Walitt B, Rasker J, Häuser W. Primary and Secondary Fibromyalgia Are The Same: The Universality of Polysymptomatic Distress. J Rheumatol. 2019;46:204-212 pubmed publisher
  2. Wolfe F, Michaud K, Wallenstein G. Scale characteristics and mapping accuracy of the US EQ-5D, UK EQ-5D, and SF-6D in patients with rheumatoid arthritis. J Rheumatol. 2010;37:1615-25 pubmed publisher
    ..Simple mapping models that use HAQ and pain have acceptable error rates, although more complex models that include mood scores and individual HAQ items substantially improve predictive accuracy. ..
  3. Wolfe F, Michaud K. Out-of-pocket expenses and their burden in patients with rheumatoid arthritis. Arthritis Rheum. 2009;61:1563-70 pubmed publisher
    ..Household income is the primary determinant of out-of-pocket burden, followed by RA severity, and type of health insurance. ..
  4. Wolfe F, Michaud K, Burke T, Zhao S. Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice. J Rheumatol. 2004;31:355-8 pubmed
    ..Duration of use can be an indicator of treatment effectiveness and/or drug acceptability, and provides additional interpretation beyond the results of clinical trials. ..
  5. Wolfe F, Caplan L, Michaud K. Rheumatoid arthritis treatment and the risk of severe interstitial lung disease. Scand J Rheumatol. 2007;36:172-8 pubmed
    ..There is no clear pattern of causal association of treatment and ILD, and there is no clear evidence to support a causal relationship between infliximab, azathioprine, and HILD. ..
  6. Wolfe F, Michaud K. The National Data Bank for rheumatic diseases: a multi-registry rheumatic disease data bank. Rheumatology (Oxford). 2011;50:16-24 pubmed publisher
  7. Wolfe F, Michaud K. The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study. Arthritis Res Ther. 2010;12:R35 pubmed publisher
    ..In the community, cost-effectiveness is substantially less than that estimated from clinical trial data. The study results represent the incremental benefit of adding biologic therapy to optimum non-biologic therapy. ..
  8. Wolfe F, Clauw D, Fitzcharles M, Goldenberg D, Katz R, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken). 2010;62:600-10 pubmed publisher
    ..It will be especially useful in the longitudinal evaluation of patients with marked symptom variability. ..
  9. Wolfe F, Häuser W, Hassett A, Katz R, Walitt B. The development of fibromyalgia--I: examination of rates and predictors in patients with rheumatoid arthritis (RA). Pain. 2011;152:291-9 pubmed publisher
    ..After diagnosis, patients move in both directions across the diagnostic criteria cut points. ..

More Information

Publications17

  1. Wolfe F, Walitt B, Katz R, Lee Y, Michaud K, Hauser W. Longitudinal patterns of analgesic and central acting drug use and associated effectiveness in fibromyalgia. Eur J Pain. 2013;17:581-6 pubmed publisher
    ..Drug costs are substantially higher because of NCAD use, but we found no evidence of clinical benefit for NCAD compared with prior therapy. ..
  2. Wolfe F, Walitt B, Rasker J, Katz R, Häuser W. The Use of Polysymptomatic Distress Categories in the Evaluation of Fibromyalgia (FM) and FM Severity. J Rheumatol. 2015;42:1494-501 pubmed publisher
    ..Although FM criteria can be clinically useful, there is no clear-cut symptom distinction between FM (+) and FM (-), and PSD categories can aid in more effectively classifying patients. ..
  3. Wolfe F, Egloff N, Häuser W. Widespread Pain and Low Widespread Pain Index Scores among Fibromyalgia-positive Cases Assessed with the 2010/2011 Fibromyalgia Criteria. J Rheumatol. 2016;43:1743-8 pubmed publisher
    ..8% of current 2011 cases. Future revisions of the 2010/2011 criteria should consider incorporating the ? 4-region requirement to avoid misclassification. ..
  4. Wolfe F, Clauw D, Fitzcharles M, Goldenberg D, Häuser W, Katz R, et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016;46:319-329 pubmed publisher
    ..These changes allow the criteria to function as diagnostic criteria, while still being useful for classification. ..
  5. Wolfe F, Michaud K, Li T, Katz R. EQ-5D and SF-36 quality of life measures in systemic lupus erythematosus: comparisons with rheumatoid arthritis, noninflammatory rheumatic disorders, and fibromyalgia. J Rheumatol. 2010;37:296-304 pubmed publisher
    ..EQ-5D and PCS are at the same levels in SLE as in RA and NIRD, but are more abnormal in SLE in the MCS and mental health domains. EQ-5D values allow preference-based comparisons with other chronic conditions. ..
  6. Wolfe F, Michaud K, Li T, Katz R. Chronic conditions and health problems in rheumatic diseases: comparisons with rheumatoid arthritis, noninflammatory rheumatic disorders, systemic lupus erythematosus, and fibromyalgia. J Rheumatol. 2010;37:305-15 pubmed publisher
    ..Depression was the most strongly associated correlate of EQ-5D quality of life, and current depression was present in about 15% of patients with RA or NIRD and 34% to 39% of those with SLE and FM. ..
  7. Wolfe F, Marmor M. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2010;62:775-84 pubmed publisher
    ..Toxicity was unassociated with age, daily dosage, or weight. These findings will aid the reformulation of screening guidelines. ..
  8. Wolfe F, Brahler E, Hinz A, Häuser W. Fibromyalgia prevalence, somatic symptom reporting, and the dimensionality of polysymptomatic distress: results from a survey of the general population. Arthritis Care Res (Hoboken). 2013;65:777-85 pubmed publisher
    ..To evaluate fibromyalgia in the general population with emphasis on prevalence, dimensionality, and somatic symptom severity...